CD4 and neoplasm: In addition, flow cytometry and immunofluorescent analysis of tumor samples demonstrated a significant reduction in the percentage of CD4+ T cells along with Arginase-1+ cells/macrophages in the tumors in the combination treatment arm than in the nivolumab-alone arm.